不良研究所

AMR Inaugural Innovation Summit Advertisement

AMR Centre newsletter
For the latest in
AMR news & events

2021 不良研究所 AMR Innovation Summit

Antimicrobials in the era of AMR Virtual event November 19th 2021 at 14:00 EDT

During World Antimicrobial Awareness Week (Nov. 18-24 2021), the 不良研究所 AMR Centre and Innovation + Partnership office are hosting the inaugural 不良研究所 AMR Innovation Summit, a virtual event aimed at discussing antimicrobial R&D and building collaborations and partnerships between 不良研究所 scientists and non-academic stakeholders.

Program

  • 14:00-14:30 Keynote speaker Erin Duffy, PhD | 鈥淏uilding a Portfolio of Products to Address AMR鈥听听 (public event)
  • 14:30-15:00 Panel discussion (public event)
  • 15:00-16:00 Industry-Academic networking event (private event)

Photo Erin Duffy Keynote speaker Erin Duffy, PhD, Chief of Research & Development, CARB-X

CARB-X is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. CARB-X funds the world鈥檚 largest early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections. Prior to CARB-X, she worked at Melinta Therapeutics (fka Rib-X Pharmaceuticals) where she became EVP, Chief Scientific Officer. Erin began her career in the Central Research Labs of Pfizer as a computational chemist and structural biologist.

Panel Discussion Challenges and Opportunities for Antimicrobial Research and Development in the Era of AMR
With experts from industry and academia.

Confirmed panelists:
Erin Duffy, PhD, Chief of Research & Development, CARB-X
Joseph Mancini, PhD, Head of Pharmacology and Biologics, Senior Director at adMare BioInnovations
Nicolas Moitessier, PhD, Professor in Chemistry (不良研究所), co-founder of Molecular Forecaster
Martin Schmeing, PhD, Professor in Biochemistry (不良研究所), Director of Centre for Structural Biology
Makeda Semret, MSc, MD, FRCPC, Associate Professor of Medicine, Infectious Diseases and Medical Microbiology (不良研究所); Lead, Antimicrobial Stewardship Program (MUHC)
Christopher Tan, PhD, Director, BD&L, Infectious Diseases & Vaccines, Merck & Co., Inc.

If you have any questions, please contact us at amrcentre [at] mcgill.ca

Back to top